List of Bortezomib drug patents
Bortezomib is owned by Fresenius Kabi Usa.
Bortezomib contains Bortezomib.
Bortezomib has a total of 1 drug patent out of which 0 drug patents have expired.
Bortezomib was authorised for market use on 06 November, 2017.
Bortezomib is available in powder;intravenous dosage forms.
The generics of Bortezomib are possible to be released after 03 November, 2032.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8962572 | FRESENIUS KABI USA | Bortezomib formulations |
Nov, 2032
(9 years from now) | |
Drugs and Companies using BORTEZOMIB ingredient
Market Authorisation Date: 06 November, 2017
Treatment: NA
Dosage: POWDER;INTRAVENOUS
More Information on Dosage
BORTEZOMIB family patents
3
United States
1
Canada
1
Australia
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic